Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05804669 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05804669 · ClinicalTrials.gov record · last posted 2026-08-19

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Name: A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome — clinical trial record (NCT05804669)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorCrinetics Pharmaceuticals Inc.

Started2023-10-12

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \[ACTH\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \[EAS\])

Protocol amendment history 1 change detected by DataLookout

2026-08-20

Enrollment closed, study ongoing

Trial Details

NCT Number	NCT05804669
Lead Sponsor	Crinetics Pharmaceuticals Inc.
Conditions	Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
Enrollment	19 participants
Start Date	2023-10-12
Primary Completion	2026-10 (estimated)
Study Completion	2026-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-19